Clovis Oncology Secures FDA Approval for Rubraca in Prostate Cancer
Rubraca is the first PARP inhibitor approved for prostate cancer.
Clovis Oncology
CLVS
CLVS
$6.14
$0.35
6.0%
Price as of August 3, 2020, 4:30 p.m. EDT
View Interactive CLVS Charts
Clovis Oncology Inc. is a biopharmaceutical company focused on acquiring developing and commercializing innovative anti-cancer agents in the United States Europe and additional international markets.
Interactive Chart
News & Analysis: Clovis Oncology
The Fool has written over 100 articles on Clovis Oncology.
Why Clovis Oncology Stock Marched Higher in April
Clovis Oncology's stock reversed course last month.
From Gilead To AstraZeneca, Investors Should Watch These Biotech Giants Right Now
Despite a busy few months with emergency use authorizations due to coronavirus, the Food and Drug Administration is expected to approve several new drugs in May.
Clovis Oncology (CLVS) Q1 2020 Earnings Call Transcript
CLVS earnings call for the period ending March 31, 2020.
Positive Prostate Cancer Results for Lynparza Are Bad News for Clovis Oncology
Strong clinical trial results from AstraZeneca and Merck just made it harder for Clovis Oncology to reach profitability.
Why Clovis Oncology, Immunomedics, and Puma Biotechnology All Spiked Today
Investors piled into cancer stocks. Here's why.
Why Clovis Oncology Stock Is Tanking Today
The biotech is getting special attention from the moody market today. Here's why.
Here's Why Clovis Oncology Has Upside Potential in 2020
The cancer-drug maker has a novel medicine that may provide growth opportunities in other areas of cancer.
What's Behind Clovis Oncology's Mixed Q4 Results
Sales of cancer drug Rubraca were higher than expected -- but so were the drugmaker's spending levels.
Clovis Oncology (CLVS) Q4 2019 Earnings Call Transcript
CLVS earnings call for the period ending December 31, 2019.
